BAK1 (BCL2-Antagonist/Killer 1) is a pro-apoptotic member of the BCL2 family that functions as a mitochondrial outer membrane permeabilization (MOMP) effector. It promotes apoptosis by forming pores in the mitochondrial outer membrane, releasing cytochrome c and other pro-apoptotic factors into the cytosol. BAK1 plays a critical role in neuronal survival and its dysregulation contributes to neurodegenerative diseases.
|
| Gene Symbol | BAK1 |
| Full Name | BCL2-Antagonist/Killer 1 |
| Chromosomal Location | 6p21.31 |
| NCBI Gene ID | 578 |
| UniProt ID | Q9YM15 |
| Ensembl ID | ENSG00000130165 |
| Protein Class | BCL2 family (pro-apoptotic) |
BAK1 is a 25 kDa protein localized primarily to the mitochondrial outer membrane. Unlike its close relative BAX, BAK1 is constitutively active and resides mainly on mitochondria. It is antagonized by anti-apoptotic BCL2 family members including BCL2, BCL-XL, and MCL1. Upon activation by BH3-only proteins (BIM, BID, PUMA), BAK1 oligomerizes to form large pores that permeabilize the mitochondrial outer membrane.
BAK1 contains several functional domains:
- BH3 Domain (aa 73-87): Critical for activation by BH3-only proteins
- BH1 Domain (aa 125-145): Required for oligomerization and pore formation
- BH2 Domain (aa 155-175): Important for heterodimerization with anti-apoptotic proteins
- Transmembrane Anchor (aa 185-205): Mitochondrial outer membrane targeting
The structure reveals a hydrophobic groove that mediates interactions with anti-apoptotic proteins and a BH3-groove that accepts the BH3 domain from activating proteins.
BAK1 is a key effector in the intrinsic (mitochondrial) apoptosis pathway:
- Activation: Cellular stress signals activate BH3-only proteins (BIM, BID, PUMA)
- Sensitization: These proteins neutralize anti-apoptotic BCL2/BCL-XL
- Direct Activation: Activated BH3-only proteins bind directly to BAK1
- Oligomerization: Activated BAK1 monomers assemble into homooligomers
- Pore Formation: BAK1 oligomers create pores in the mitochondrial outer membrane
- Cytochrome c Release: Mitochondrial intermembrane space proteins (cytochrome c, SMAC, Omi) are released
- Caspase Activation: Cytosolic cytochrome c triggers apoptosome formation and caspase-9 activation
BAK1 also participates in:
- Mitochondrial Dynamics: Regulation of mitochondrial fission and fusion
- Autophagy: Selective mitophagy through interaction with autophagy receptors
- Cell Cycle Regulation: Checkpoint control in response to DNA damage
BAK1-mediated neuronal apoptosis contributes to AD progression:
- Aβ-Induced Apoptosis: Amyloid-beta oligomers increase BAK1 activation in neurons
- Tau Pathology: Hyperphosphorylated tau enhances BAK1-mediated cytochrome c release
- Synaptic Loss: BAK1 activation in synapses precedes overt neuronal death
- Therapeutic Target: BAK1 inhibitors may protect neurons from Aβ toxicity
- Mitochondrial Dysfunction: BAK1 activation is a downstream effect of mitochondrial complex I inhibition
- α-Synuclein Toxicity: BAK1 mediates dopaminergic neuron death induced by α-synuclein aggregates
- Leucine-Rich Repeat Kinase 2 (LRRK2): LRRK2 G2019S mutations may sensitize neurons to BAK1-dependent apoptosis
¶ Stroke and Ischemia
- Acute Neuronal Death: BAK1 is rapidly activated following cerebral ischemia
- Excitotoxicity: Glutamate-induced excitotoxicity activates BAK1-mediated apoptosis
- Therapeutic Window: BAK1 inhibition may provide neuroprotection if administered early
- Motor Neuron Vulnerability: BAK1 activation contributes to sporadic and familial ALS
- ** SOD1 Mutations**: Mutant SOD1 sensitizes motor neurons to BAK1-dependent apoptosis
- TARDBP (TDP-43): TDP-43 pathology correlates with increased BAK1 activation
- Secondary Injury: BAK1-mediated apoptosis contributes to progressive neuronal loss
- Axonal Degeneration: BAK1 activation in axons following trauma
BAK1 is expressed throughout the central nervous system:
- Neurons: Moderate expression in cortical, hippocampal, and dopaminergic neurons
- Astrocytes: Lower expression compared to neurons
- Microglia: Constitutive expression; upregulated in neuroinflammation
Several BAK1-selective inhibitors have been developed:
- BAK1 Inhibitor (BAK-IN-1): Selectively binds BAK1, prevents oligomerization
- ABT-737: Originally developed as BCL2/BCL-XL inhibitor, also has BAK1 activity at higher doses
- S63845: MCL1 inhibitor indirectly blocks BAK1 activation
- Systemic Toxicity: BAK1 inhibition may impair immune cell function and tissue homeostasis
- Blood-Brain Barrier: Drug delivery to CNS remains challenging
- Apoptotic vs. Non-Apoptotic Functions: Blocking all BAK1 functions may have unintended consequences
- With Anti-Amyloid Therapies: BAK1 inhibition may enhance neuronal survival during Aβ clearance
- With Neurotrophic Factors neuro: Combinedprotection strategies
- With Anti-inflammatory Agents: Addressing multiple death pathways
¶ Interactions and Regulation
- BIM (BCL2L11)
- BID
- PUMA (BBC3)
- NOXA (PMAIP1)
- BCL2
- BCL-XL (BCL2L1)
- MCL1
- BCL2A1
- p53-mediated transcriptional activation of BAK1
- JNK/c-JUN pathway enhances BAK1 activation
- PI3K/AKT phosphorylates and inhibits BAK1
The study of Bak1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- BAK1 structure and function (J Mol Biol, 2003)
- BAK1 in apoptosis (Science, 2001)
- BAK1 in neuronal death (J Neurosci, 2009)
- BAK1 in Alzheimer's disease (Neurobiol Aging, 2012)
- BAK1 in Parkinson's disease (Cell Death Differ, 2015)
- Mitochondrial apoptosis in neurodegeneration (Nat Rev Neurosci, 2014)
- BAK1 oligomerization mechanism (Cell, 2008)